Prostate cancer is a very common disease, with more than 3 million cases in the US per year. Currently there aren’t good options for men whose disease progresses beyond the first line of therapy. Dr. Kelly’s project aims to improve treatment options for men whose prostate cancer no longer responds to hormone-depletion treatments. The work will attempt to identify patients who will benefit from chemotherapy or abiraterone (Zytiga) treatment. As part of the study, the researchers will also try to determine how long a patient should be given chemotherapy for the best outcome.
Kelly’s team, which includes co-leadership from Karen Knudsen, Ph.D., Interim Director of the Sidney Kimmel Cancer Center and Robert Den, M.D., Assistant Professor of Radiation Oncology, was chosen because it was considered one of the best proposals to “revolutionize the way prostate cancer is diagnosed and managed,” says Jonathan W. Simons, MD, president and CEO of the Prostate Cancer Foundation in a press release. “Our focus in 2015 is to fast-track discoveries that will have immediate clinical relevancy for advanced prostate cancer.”